Madrigal Pharmaceuticals, Inc. (MDGL): Price and Financial Metrics
MDGL Price/Volume Stats
| Current price | $269.20 | 52-week high | $322.67 |
| Prev. close | $276.48 | 52-week low | $57.21 |
| Day low | $268.50 | Volume | 235,221 |
| Day high | $280.52 | Avg. volume | 381,426 |
| 50-day MA | $277.45 | Dividend yield | N/A |
| 200-day MA | $190.58 | Market Cap | 4.92B |
MDGL Stock Price Chart Interactive Chart >
Madrigal Pharmaceuticals, Inc. (MDGL) Company Bio
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania.
Latest MDGL News From Around the Web
Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
Madrigal Pharmaceuticals Supports International NASH Day on June 8Company expands support for NASH disease education through patient advocacy partnerships and a new digital campaign for patients with at-risk NASHCONSHOHOCKEN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced its support for the sixth International NASH Day, taking place on June 8, 2023. Led by the Global Liver Institute (GLI) in part |
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor ConferencesCONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at two upcoming investor conferences: Jefferies Healthcare Conference2:30 pm ET on Wednesday, June 7, 2023. Goldman Sachs Global Healthcare Conference 12:20 pm ET on Tuesday, June 13, 2023. The fireside chats will be |
Why Madrigal Pharmaceuticals Stock Is Marching Higher TodayShares of the clinical-stage drugmaker Madrigal Pharmaceuticals (NASDAQ: MDGL) were up by 6.2% on elevated volume as of 12:16 p.m. ET Wednesday. The biotech appears to be benefiting from two key tailwinds. First, a Food and Drug Administration (FDA) panel voted overwhelmingly last Friday against approving Intercept Pharmaceuticals' (NASDAQ: ICPT) candidate, obeticholic acid, for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH). |
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two DaysHepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers in the phase II ALTITUDE-NASH study in advanced NASH patients. |
Intercept (ICPT) NASH Treatment Fails to Get GIDAC RecommendationIntercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available. |
MDGL Price Returns
| 1-mo | -10.16% |
| 3-mo | 11.41% |
| 6-mo | 302.33% |
| 1-year | 262.31% |
| 3-year | 132.77% |
| 5-year | -4.86% |
| YTD | -7.25% |
| 2022 | 242.52% |
| 2021 | -23.77% |
| 2020 | 22.02% |
| 2019 | -19.17% |
| 2018 | 22.80% |
Loading social stream, please wait...